Evidence map›Paper›PMID 27191724›Full record

Observational studyPloS one2016

Using Big Data to Assess Prescribing Patterns in Greece: The Case of Chronic Obstructive Pulmonary Disease.

Kyriakos Souliotis, Chara Kani, Manto Papageorgiou, Dimitrios Lionis, Konstantinos Gourgoulianis

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Observational
  3. Observational
  4. Impact of the financial crisis on COPD burden: Greece as a case study.European respiratory review : an official journal of the European Respiratory Society · 2018
    Review
  5. Article
  6. Determinants of medical prescriptions for COPD care: an analysis of the EPOCONSUL clinical audit.International journal of chronic obstructive pulmonary disease · 2018
    Observational
  7. The pharmacological cost of COPD during Greek economic crisis.International journal of chronic obstructive pulmonary disease · 2017
    Article
  8. The direct and indirect costs of managing chronic obstructive pulmonary disease in Greece.International journal of chronic obstructive pulmonary disease · 2017
    Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Kyriakos SouliotisFaculty of Social and Political Sciences, University of Peloponnese, Corinth, Greece.
Chara KaniMedicines Division, National Organization for Healthcare Services Provision (EOPYY), Athens, Greece.
Manto PapageorgiouDepartment of Social and Educational Policy, University of Peloponnese, Corinth, Greece.
Dimitrios LionisDepartment of Social and Educational Policy, University of Peloponnese, Corinth, Greece.
Konstantinos GourgoulianisDepartment of Respiratory Medicine, Medical School. University of Thessaly, Larissa, Greece.
University of Peloponnese · GRNational and Kapodistrian University of Athens · GRNational Public Health Organization · GRUniversity of Thessaly · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionChronic Obstructive Pulmonary Disease (COPD) is one of the top leading causes of death and disability, and its management is focused on reducing risk factors, relieving symptoms, and preventing exacerbations. The study aim was to describe COPD prescribing patterns in Greece by using existing health administrative data for outpatients.

methodsThis is a retrospective cross-sectional study based on prescriptions collected by the largest social insurance fund, during the first and last trimester of 2012. Selection criteria were the prescription of specific active substances and a COPD diagnosis. Extracted information included active substance, strength, pharmaceutical form and number of packages prescribed, diagnosis, time of dispensing, as well as insurees' age, gender, percentage of co-payment and social security unique number. Statistical analysis included descriptive statistics and logistic regression.

results174,357 patients received medicines for COPD during the study period. Patients were almost equally distributed between male and female, and age above 55 years was strongly correlated with COPD. Most patients received a long-acting beta agonist plus inhaled corticosteroid combination (LABA +ICS), followed by long-acting muscarinic agonist (LAMA). 63% patients belonging in the 35-54 age received LABA+ICS. LAMA was prescribed more frequently among males and was strongly correlated with COPD.

conclusionThe study provides big data analysis of Greek COPD prescribing patterns. It highlights the need for appropriate COPD classification in primary care illustrating the role of electronic prescribing in ensuring appropriate prescribing. Moreover, it indicates possible gender differences in treatment response or disease severity, and the impact of statutory co-payments on prescribing.

Indexed as

Adrenal Cortex HormonesAdrenergic beta-AgonistsAdultAgedAge FactorsDrug Therapy, CombinationFemaleGreeceHumansMaleMiddle AgedMuscarinic AgonistsPractice Patterns, Physicians'Pulmonary Disease, Chronic ObstructiveSex FactorsSocial SecurityAdrenal Cortex HormonesAdrenergic beta-AgonistsMuscarinic Agonists

Identifiers

PMID27191724
PMCPMC4871446
OpenAlexW2402658637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.